Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$711K Buy
13,555
+142
+1% +$7.51K 0.06% 193
2026
Q1
$740K Buy
13,413
+2,071
+18% +$112K 0.07% 174
2025
Q4
$556K Buy
11,342
+1,342
+13% +$62.6K 0.07% 199
2025
Q3
$432K Sell
10,000
-589
-6% -$23K 0.06% 235
2025
Q2
$407K Buy
10,589
+4,273
+68% +$163K 0.06% 227
2025
Q1
$245K Buy
6,316
+6,228
+7,077% +$228K 0.04% 354
2024
Q4
$2.98K Buy
88
+22
+33% +$792 ﹤0.01% 1959
2024
Q3
$2.7K Buy
66
+42
+175% +$1.72K ﹤0.01% 1490
2024
Q2
$924 Hold
24
﹤0.01% 1690
2024
Q1
$1.03K Sell
24
-676
-97% -$27.9K ﹤0.01% 1533
2023
Q4
$25.9K Buy
700
+676
+2,817% +$24.3K 0.01% 403
2023
Q3
$870 Hold
24
﹤0.01% 1563
2023
Q2
$855 Hold
24
﹤0.01% 1658
2023
Q1
$854 Hold
24
﹤0.01% 1482
2022
Q4
$843 Hold
24
﹤0.01% 1335
2022
Q3
$1K Hold
24
﹤0.01% 1237
2022
Q2
$1K Buy
+24
New +$1.32K ﹤0.01% 1259
2021
Q3
Sell
-220
Closed -$11K 1515
2021
Q2
$11K Buy
+220
New +$10.6K ﹤0.01% 683
2020
Q4
Sell
-247
Closed -$11K 1416
2020
Q3
$11K Hold
247
﹤0.01% 624
2020
Q2
$12K Hold
247
0.01% 568
2020
Q1
$11K Buy
+247
New +$13.2K 0.01% 525
2018
Q1
Sell
-137
Closed -$6K 1550
2017
Q4
$6K Buy
+137
New +$6.33K ﹤0.01% 1065

Other funds holding GSK

Versant Capital Management's GSK Position: Q2 2026 in Review

Versant Capital Management increased its GSK (GSK) stake by 1.1% in Q2 2026, buying an estimated $7.51K and bringing the position to 13,555 shares worth $711K. The position accounts for 0.06% of the portfolio, ranked #193.

Versant Capital Management first reported a position in GSK in Q4 2017 and has held it in 22 quarters since. The position peaked at $740K in Q1 2026. 161 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Versant Capital Management held 13,555 shares of GSK worth $711K as of Q2 2026.
  • Versant Capital Management bought 142 GSK shares in Q2 2026, an estimated $7.51K.
  • GSK made up 0.06% of Versant Capital Management's portfolio in Q2 2026, its #193 holding.
  • Versant Capital Management first reported a position in GSK in Q4 2017 and has held it in 22 quarters since.
  • Versant Capital Management's GSK position peaked at $740K in Q1 2026.
  • 161 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.